Health and Healthcare
Keytruda, COVID-19 Hopes Prompt Merck Earnings Beat, Rosy Outlook
Published:
When Merck & Co. (NYSE: MRK) reported its second-quarter financial results before the markets opened on Wednesday, the pharmaceutical giant said that it had earnings per share (EPS) of $1.37 and $10.9 billion in revenue. That compared with consensus estimates of $1.04 in EPS and $10.39 billion in revenue. The same period of last year reportedly had $1.30 in EPS and $11.76 billion in revenue.
Merck has a few irons in the COVID-19 fire, and it is accelerating two vaccine development efforts and a novel antiviral candidate. The company has a collaboration with the International AIDS Vaccine Initiative for developing a vaccine, and it acquired Themis, which has a vaccine candidate as well. Separately, Merck has a collaboration with Ridgeback Bio for a COVID-19 antiviral treatment.
In terms of the numbers, worldwide sales decreased by 8%, or 5% excluding foreign exchange. This was largely driven by Keytruda sales increasing 29% year over year to $3.4 billion.
Animal Health sales totaled $1.1 billion for the second quarter, a decrease of 2% compared with the second quarter of last year. Excluding the unfavorable effect from foreign exchange, Animal Health sales grew 3%. Performance in livestock products reflects lower demand driven by reduced protein and milk demand due to restaurant and school closures resulting from the COVID-19 pandemic.
Looking ahead to the 2020 full year, Merck expects to see earnings of $5.63 to $5.78 per share and revenue between $47.2 billion and $48.7 billion. Consensus estimates call for $5.31 in EPS and $47.33 billion in revenue for 2019.
Management noted that it remains confident that Merck will drive strong long-term growth based on underlying demand for its unique portfolio of innovative medicines, vaccines and animal health products.
Merck stock traded up about 1% at $80.11 on Friday, in a 52-week range of $65.25 to $92.64. The consensus price target is $93.00.
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.